Abstract The laminin-binding integrin a6b4 plays key roles in both normal epithelial and endothelial cells and during tumor cell progression, metastasis, and angiogenesis. Previous cysteine mutagenesis studies have suggested that palmitoylation of a6b4 protein supports a few integrindependent functions and molecular associations. Here we took another approach and obtained strikingly different results. We used overexpression and RNAi knockdown in multiple cell types to identify protein acyl transferase DHHC3 as the enzyme responsible for integrin b4 and a6 palmitoylation. Ablation of DHHC3 markedly diminished integrin-dependent cellular cable formation on Matrigel, integrin signaling through Src, and b4 phosphorylation on key diagnostic amino acids (S1356 and 1424). However, unexpectedly, and in sharp contrast to prior a6b4 mutagenesis results, knockdown of DHHC3 accelerated the degradation of a6b4, likely due to an increase in endosomal exposure to cathepsin D. When proteolytic degradation was inhibited (by Pepstatin A), rescued a6b4 accumulated intracellularly, but was unable to reach the cell surface. DHHC3 ablation effects were strongly selective for a6b4. Cell-surface levels of *10 other proteins (including a3b1) were not diminished, and the appearance of hundreds of other palmitoylated proteins was not altered. Results obtained here demonstrate a new substrate for the DHHC3 enzyme and provide novel opportunities for modulating a6b4 expression, distribution, and function.
Introduction
Integrins a6b4 and a6b1 mediate cell adhesion to various isoforms of laminin [1] . The a6b4 integrin, widely expressed in many epithelial cells, is a major component of hemidesmosomes [2] and plays a key role during skin development [3, 4] . The a6b1 integrin is present on platelets [5] and on multiple types of leukocytes, where it can contribute to immune functions [6, 7] . Integrins a6b1 and a6b4 also may play central roles in human papilloma virus binding to cells [8] . In cancer, both integrins contribute to tumor growth, invasion, metastasis, angiogenesis, epithelial-mesenchymal-transition (EMT), and drug resistance [9] [10] [11] [12] , and a6 is frequently used as a marker to help define stem cell/tumor initiating cell subpopulations [13, 14] . Consequently, these integrins have emerged as potential cancer drug targets.
The a6b4 and a6b1 integrins (together with lamininbinding integrins a3b1 and a7b1) share multiple features that distinguish them from all other integrins. First, they associate most closely with tetraspanin proteins, especially CD151 [15, 16] , leading to residence within tetraspaninenriched microdomains (TEMs) [17] . Second, they undergo post-translational palmitoylation at membraneproximal cysteine sites [18, 19] . The b4 subunit contains seven potential sites, and there is one site each in the a6, a3, and a7 subunits. Mutation of b4 membrane-proximal cysteines prevented palmitoylation, but did not diminish a6b4 cell-surface expression [18, 19] . While on the cell surface, palmitoylation-deficient a6b4 mutants showed reduced signaling through p130Cas and Src family kinases, accompanied by diminished cell proliferation and spreading [18, 19] . These defects are likely linked to diminished physical and functional association of a6b4 mutants with tetraspanin proteins [18] .
Mutagenesis is useful for study of protein palmitoylation, but is less than ideal for two reasons. First, removal of membrane-proximal cysteines could affect protein structure and function in a manner that goes beyond simply losing palmitoylation sites. Second, it is technically challenging to replace endogenous proteins with palmitoylation-deficient mutants in various cell types. Consequently, palmitoylation-deficient mutants have often been over-expressed in unnatural cellular environments, yielding potentially misleading results. As an alternative, we sought to identify and eliminate the key protein acyl transferase (PAT) responsible for integrin palmitoylation.
Protein acyl transferases within the DHHC family are responsible for many mammalian palmitoylation events. This family has 23 members, distributed among the Golgi, ER, and the plasma membrane [20] [21] [22] . They are polytypic membrane proteins, each with 4-6 transmembrane domains. There is a 50-amino-acid cysteine-rich domain (CRD) between transmembrane domains 2 and 3, on the cytosolic side of the molecule. This CRD domain (sometimes called the DHHC-CRD domain) contains a conserved Asp-His-His-Cys (DHHC) motif critical for catalytic activity [20] . For transmembrane proteins, palmitoylation of membrane-proximal cysteines can (a) regulate protein-protein interactions, e.g., for AMPA [23] and CD151 [24] , (b) affect lipid bilayer positioning, e.g., for LRP6 [25] , (c) regulate protein trafficking, e.g., for transferrin receptor [26] , and (d) affect protein stability, e.g., for CD9, CD151, and CCR5 [24, 27] . Although there are many transmembrane proteins that undergo palmitoylation [28] , in most cases the specific DHHC proteins involved have not been identified.
Tetraspanin proteins are palmitoylated [29] , and palmitoylation-deficient mutants show altered functions and reduced lateral associations with other proteins, including integrins [30] [31] [32] . DHHC2 was identified as the PAT most important for palmitoylation of tetraspanin proteins CD9 and CD151 [24] . Consistent with mutagenesis results, DHHC2 ablation also caused reduced tetraspanin associations with other proteins [24] . However, despite close proximity of a6b4 and a6b1 integrins to tetraspanins, integrin palmitoylation was not dependent on DHHC2 [24] . Here we identify DHHC3 as the DHHC family member most responsible for a6b4 and a6b1 palmitoylation. Previously DHHC3/GODZ was shown to affect palmitoylation of the c2 subunit of GABA (A) receptors [23, 33] and to contribute (along with DHHC7) to palmitoylation of Ga proteins [34] and RGS4 [35] . Our study is now the first demonstration of DHHC3 affecting palmitoylation of widely expressed type I transmembrane proteins, such as the a6 and b4 integrin subunits.
Ablation of DHHC3 markedly diminished a6b4 and a6b1 palmitoylation and function, while not affecting palmitoylation of integrin a3b1 or a large number of other proteins. However, the consequence of reduced integrin palmitoylation due to DHHC3 ablation contrasts sharply with results obtained by b4 cysteine mutagenesis. Whereas b4 palmitoylation-deficient mutants were stable and readily expressed at the cell surface [18, 19] , unpalmitoylated b4 in DHHC3-ablated cells shows enhanced susceptibility to proteolytic degradation and markedly reduced cell-surface expression. These results provide unexpected new insights into integrin palmitoylation, and provide a novel way to modulate a6b4 and a6b1 integrin functions, without directly targeting the a6 or b4 subunits themselves.
Materials and methods

Cells, antibodies, and reagents
Human Embryonic Kidney HEK 293 cells and MDA-MB-231 cells were obtained from ATCC and cultured in DMEM media with 10% FBS and antibiotics. Prostate cancer (PC3) cells were cultured in RPMI media. Monoclonal (mAb, MAB1964) and polyclonal (pAb, AB1922) antibodies to b4 integrin were from Chemicon. Polyclonal antibody to b4 S1424 [36] and S1356 [37] were described earlier. Other antibodies were anti-a6 integrin mAb GoH3 (BD Biosciences) and pAb H-87 (Santa Cruz), anti-DHHC3 pAb ab31387 (Abcam), anti-M2 Flag mAb (Sigma), anti-CD9 mAb MM2/57 (Millipore), anti-CD71 mAb 3B8 2A1 (Santa Cruz), anti-Src (Santa Cruz), anti-pSrc pAb (Cell Signaling). Antibodies to a3 (mAb A3X8), b1 (TS2/16), CD151 (5C11), and EWI-F (MX-1) have been described previously [18] . Pepstatin A (used at 100 lM), Leupeptin (100 lM), Bafilomycin A (150 nM) were obtained from Sigma, and E64 (100 lM) was from Calbiochem. [ 3 H]-labeled palmitic acid was purchased from Perkin-Elmer. [24] . Densitometry quantitation of protein after blotting was performed using Image Quant, version 5.2 software (GE Healthcare).
Immunofluorescence and flow cytometry
Control or DHHC3 stable knockdown cells were fixed with 4% paraformaldehyde and in some experiments were also permeabilized using 0.1% Triton X-100. After incubation for 1 h in 5% horse serum, fixed cells were incubated with specific antibodies overnight at 4°C. After washing with PBS, cells were incubated with respective secondary antibodies conjugated to fluorophores (Alexa Fluor 488 or Alexa Fluor 594) for 1 h at RT. Finally, after washing five times with PBS, slides were mounted with Prolong Gold antifade mounting media with DAPI (Invitrogen). Pictures were taken using a Leica SP5X laser scanning confocal microscope (Leica Microsystems, Chicago, IL) with a 639 magnification. Quantitation of staining intensity of individual cells was done using Scion Image software (Scion Corp., Frederick, MD). Flow cytometry was performed using a FACS Calibur (Becton-Dickinson, Bedford, MA) as previously described [24] .
Cell signaling and cable formation
For integrin-triggered signaling, cells were starved overnight and suspended in culture media with no FBS. Equal numbers of cells from control or DHHC3 knockdown samples were incubated with IgG, a6 and b4 antibodies for 1 h at 4°C with shaking. After incubation, cells were plated on dishes precoated with anti-mouse or anti-rat IgG for 30 min at 37°C. Finally, cells were lysed and proteins were purified and separated on SDS-PAGE gel and then blotted for p-Src and total Src. For cable formation, cells were suspended in a media containing 5% FBS. Matrigel (300 ll) was added to a 24-well plate and allowed to solidify. Equal numbers of cells were plated on top of the Matrigel in triplicate for each condition. Plates were incubated at 37°C and photographed after 24 h [at 29 magnification, using monochrome chargecoupled device camera (RT SPOT, Diagnostic Instruments) on an Axiovert 135 inverted microscope (Zeiss Co.)]. For quantitation, numbers of closed areas were counted from different fields in each well for each condition. The data was compiled and plotted from three independent experiments each with three replicates.
Results
Screening of DHHC proteins for effects on integrin palmitoylation
DHHC-mediated protein palmitoylation can occur in the Golgi, in the endoplasmic reticulum, and at the plasma membrane [22] . The Golgi-disrupting agent brefeldin A inhibited palmitoylation of the integrin b4 subunit (by 55%) as seen upon immunoprecipitation of endogenous b4 from [
3 H]palmitate-labeled MDA-MB-231 cells (Fig. 1a , lanes 1, 2). In control experiments, palmitoylation of tetraspanin CD9, which is known to occur in the Golgi [24] , was substantially inhibited, whereas palmitoylation of CD9 partner protein EWI-2 was relatively unaffected by brefeldin A (Fig. 1a, lanes 3, 4) . Hence, we focused attention on the 12 DHHC proteins known to at least partially reside in the Golgi [22, 38] . Among these, overexpression of DHHC3, and to a lesser extent DHHC15 and DHHC2, yielded elevated b4 palmitoylation in HEK293 cells (Fig. 1b, top panel) . Also elevated is palmitoylation/protein (third panel), normalized for b4 protein expression (second panel). Palmitoylation of the integrin a6 subunit also appeared to be elevated in parallel with b4 (top panel). The bottom panel in Fig. 1b establishes the presence of each overexpressed DHHC protein in HEK293 cells.
In a follow-up experiment, siRNA knockdown of DHHC3 (but not DHHC2) caused a reduction in b4 palmitoylation (by *47%) in HEK293 cells (Fig. 1c) . This result is consistent with previous results [24] showing that DHHC2 does not affect b4 integrin palmitoylation. In a side-by-side comparison, b4 palmitoylation was increased (over twofold) upon overexpression of DHHC3, and decreased (by *70%) upon knockdown of endogenous DHHC3 in HEK293 cells (Fig. 1d) . DHHC15 was not considered further because it is expressed minimally or not at all in many cells in which b4 is highly palmitoylated. Knockdown of other Golgi-resident DHHC's did not decrease b4 palmitoylation. Among commonly expressed laminin-binding integrin subunits (a3, a6, b4), DHHC3 showed surprising selectivity for a6 and b4 but not a3. DHHC3 ablation did not affect appearance of either palmitoylated a3 or abundantly associated CD151, immunoprecipitated using either anti-a3 antibody (Fig. 2, lanes 1, 2) , or anti-b1 antibody (lanes 3, 4). The abundance of a3 likely obscures possible changes in a6 levels in lanes 3 and 4. However, direct immunoprecipitation of a6 shows that DHHC3 ablation diminishes appearance of palmitoylated b4, a6, and associated CD151, each by 62-70% (Fig. 2, lanes 5, 6) . Likewise, immunoprecipitation of b4 revealed decreased recovery (by 54-65%) of palmitoylated b4, a6, and CD151 (Fig. 2, lanes  7, 8) . Lane 5 contains 2.5-fold more a6 and 42% less labeled b4 compared to lane 7. This indicates that (a) substantial a6b1 was present, and (b) there is decreased recovery of both a6b1 and a6b4 in lane 6. To analyze a6b1 in the absence of a3, a3b1 was immunodepleted from PC3 cell lysate, and then a6b1 was immunoprecipitated using anti-b1 antibody. Once again, recoveries of palmitoylated a6 and associated CD151 were substantially reduced (by 42-51%) due to DHHC3 ablation (Fig. 2, lanes 9, 10) . Note that CD151 is not a substrate for DHHC3 [24] (Supplemental Fig. S2 ). An explanation for decreased CD151 palmitoylation is provided below (see Fig. 4 ).
Effects of DHHC3 ablation on a6b4-dependent functions
Having established that DHHC3 affects integrin a6b4 palmitoylation, we next looked at effects of DHHC3 ablation on functions involving a6 and/or b4. First, we analyzed Matrigel cable formation, which is a model for a6 integrin-dependent extracellular matrix remodeling [39] . DHHC3-ablated PC3 prostate tumor cells and control knockdown cells differed significantly in ability to form cables on Matrigel (Fig. 3a) . Second, we looked for differences in antibody-triggered integrin signaling in PC3 cells. Activation of p-Src (Y416) was increased by 47% upon a6 stimulation and 72% upon b4 stimulation, compared to control IgG stimulation in vector control cells. On the other hand, DHHC3 KD cells showed an 8% decrease in p-Src (Y416) activation after a6 and b4 stimulation as compared to control IgG stimulation.
DHHC3 effects on endogenous integrin palmitoylation, distribution, and protein expression
To understand further the basis for the functional differences observed in Fig. 3 , we analyzed stable DHHC3 knockdown effects on endogenous a6b4 palmitoylation, expression, and localization in representative prostate (PC3) and breast (MDA-MB-231) carcinoma cell lines. Stable ablation of DHHC3 not only reduced recovery of [ 3 H]-labeled b4 and a6 in these cells (Fig. 4a, b) but also caused diminished expression of both b4 and a6 proteins as seen by immunoblotting (Fig. 4a, b, bottom panels) . Diminished expression of b4 and a6 was confirmed by immunofluorescence staining of PC3 cells (Fig. 4c) and by cell-surface flow cytometry (Supplemental Fig. S3 ). Cellsurface expression of nine other proteins was not diminished (Supplemental Fig. S3 ). Targeting of DHHC3 (by siRNA) at a different nucleotide region confirmed that ablation of endogenous DHHC3 causes reductions in both [ 3 H] palmitoylation and expression of a6b4, in both MDA-MB-231 and PC3 cells (Supplemental Fig. S2, left panels) . Reduced a6 and b4 protein expression explains why there is also a decrease in appearance of integrin-associated, [ 3 H]-labeled CD151 (Figs. 2, 4, S2) , even though CD151 is not a substrate for DHHC3. Expression of b4 and a6 was not only diminished upon DHHC3 ablation but also 
and DHHC3 (DHHC3 KD) knockdown were plated on polymerized Matrigel in complete growth medium in 24-well plates. After 24 h, photographs were taken and mean % cable formation was quantitated (n = 3). b PC3 cells with vector knockdown (V) and DHHC3 knockdown (D3) were incubated with control mouse IgG, with rat anti-a6 mAb, or with mouse anti-b4 mAb for 1 h at 4°C. Cells coated with primary antibody were then plated in wells coated with goatanti-mouse or goat-anti-rat IgG, and incubated for 30 min at 37°C, to trigger integrin signaling. After cell lysis, proteins were separated and blotted for the indicated signaling molecules. Density units in the bar graph represent p-Src(416)/Total c-Src (from top two panels). The bottom two panels show an actin loading control and confirm DHHC3 knockdown DHHC3 palmitoylates a6b4 integrin 2237 became more evenly distributed throughout the area of permeabilized cells (Fig. 4c, d ). These results are consistent with loss of cell-surface expression.
Rescue of protein expression after DHHC3 ablation Results in Fig. 4 and Fig. S2 suggest that DHHC3 ablation causes loss of palmitoylation, which leads to protein destabilization. To test this hypothesis, it was necessary to inhibit, at least partially, the loss of protein expression. Among inhibitors tested (Leupeptin, E64, bafilomycin A, Pepstatin A, ALLM, lactacystin), the one best able to rescue b4 integrin protein expression in DHHC3-ablated PC3 tumor cells (from 37-42% back up to 73%; Fig. 5a ) was Pepstatin A (a cathepsin D protease inhibitor). With b4 protein expression partially stabilized (*twofold increased in the presence of Pepstatin A), the palmitoylation/protein ratio for endogenous b4 integrin was reduced by *50% in DHHC3-ablated cells as compared to control knockdown cells (Fig. 5b) . In the whole cell lysate (Fig. 5c ), palmitoylation was unchanged for many unidentified [ 3 H]-labeled proteins. The bottom panel in Fig. 5c confirms the loss of DHHC3 expression in two replicate samples.
Unpalmitoylated and palmitoylated b4 differ with respect to cell-surface expression Ablation of DHHC3 in PC3 cells caused intracellular b4 expression to decrease by *50% (Fig. 6a, lanes 5, 6) . However, intracellular b4 expression was largely retained (only 15% decrease) if Pepstatin A was present (lanes 8, 7) . By contrast, DHHC3 ablation caused a 64% loss of cell surface b4 protein (lanes 1, 2) , which was not prevented by Pepstatin A (67% loss; lanes 4, 3) . Densitometry numbers Table 1 . Hence, blocking of cathepsin D may protect or rescue unpalmitoylated b4 protein intracellularly, but it does not appear to get to the cell surface. Consistent with the stabilization of intracellular unpalmitoylated b4, the palmitoylation/protein ratio decreased markedly (by 41%) when Pepstatin A was present during DHHC3 ablation. By contrast, DHHC3 ablation caused the palmitoylation/protein ratio to decrease by only 12.9% on the cell surface when Pepstatin was present (Supplemental Table 1 ). Hence, intracellular b4 is relatively unpalmitoylated, whereas the cell surface is enriched for the small amount of remaining palmitoylated b4. When Pepstatin A was absent, DHHC3 ablation had less effect on the b4 palmitoylation/protein ratio (decreased by 3% on the cell surface; 14.5% intracellularly; Supplemental Table 1 ).
An immunofluorescence staining experiment confirmed that DHHC3 ablation causes b4 disappearance, as seen either by staining of total b4 (in permeabilized cells, Supplemental Fig. S4c ) or cell surface b4 (unpermeabilized cells, Fig. S4d ). After Pepstatin A treatment of PC3 cells, total b4 no longer was lost due to DHHC3 ablation (Supplemental Fig. S4g ), whereas cell-surface b4 expression still was substantially decreased (Supplemental Fig. S4h) . These results again suggest that palmitoylation-deficient b4 can be rescued intracellularly (with Pepstatin A), but then does not reach the cell surface. To further support this notion, we analyzed phosphorylation of b4 integrin, which occurs proximal to the cell surface, at sites (S1424 and 1356) linked to hemidesmosome turnover [36, 37, 40] . As seen in Fig. 6c , there is a loss of S1424 and 1356 phosphorylation in DHHC3 ablated samples and this loss (measured as phosphorylation/protein) is even more obvious in the presence of Pepstatin A (when intracellular b4 integrin expression is partially rescued).
Upon DHHC3 ablation, the amount of intracellular a6 protein decreased by 59% in untreated cells (Fig. 6a , bottom panel, lanes 5, 6) and by 52% in Pepstatin A-treated cells (lanes 7, 8) . Hence, Pepstatin A fails to rescue a6 from intracellular degradation. DHHC3 ablation caused cell surface a6 to decrease by 71-73% (Fig. 6a, bottom  panel, lanes 1-4) , comparable to the decrease seen for b4 protein (64-67%, lanes 1-4; and also see Supplemental Table 1 ). DHHC3 ablation, with or without Pepstatin A treatment, had little or no detectable effect on the palmitoylation of numerous unidentified proteins in PC3 whole cell lysates (Fig. 6c) .
Discussion
DHHC3 palmitoylates a6b4 integrin
After narrowing the focus to 12 Golgi-resident DHHC enzymes, we utilized over-expression studies, shRNA knockdown, siRNA knockdown, and three different cellular environments to demonstrate that DHHC3 is the major PAT responsible for palmitoylation of a6b4 integrin.
Although other DHHCs, such as DHHC2, partially stimulated b4 palmitoylation when overexpressed, knockdown of DHHC2 and other Golgi-resident DHHCs (other than DHHC3) did not diminish palmitoylation. We showed previously that DHHC2 palmitoylates tetraspanin proteins, but not a6b4 integrin [24] . Here we find that DHHC3 palmitoylates a6b4, but not tetraspanins (e.g., CD9, CD151). DHHC3 knockdown also failed to affect the palmitoylation of CD71 (transferrin receptor) and numerous unidentified proteins present in whole cell lysates in multiple experiments. These results are consistent with DHHC3 showing considerable substrate selectivity, while acting directly on a6b4. DHHC3 may have several other substrates. Knockdown of DHHC3 decreased palmitoylation of multiple heterotrimeric G protein alpha subunits [34] , and co-expression of DHHC3 promoted palmitoylation of regulator of G-protein signaling 4 (RGS4) protein [35] , the c2 subunit 1-4) . After removal of cellsurface proteins, the remaining lysate (containing intracellular b4) was immunoprecipitated using anti-b4 mAb, and intracellular proteins were visualized (lanes 4-8) . b PC3 cells, with or without Pepstatin A treatment, with control or DHHC3 stable knockdown vectors, were lysed in 1% Triton X-100 buffer. Samples were then blotted for b4 phosphorylated at S1424 and S1356 and the same membranes were blotted for total b4 (2nd and 4th panels) after stripping. Density units in the bar graph represent phospho b4 (S1424)/Total b4 and b4 (S1356)/Total b4. c [ of GABA (A) receptors [33] , cysteine-string protein (CSP) [41] , and nearly a dozen other proteins [42] . However, in the majority of cases, co-expression results have not been confirmed by DHHC3 knockdown/ablation studies.
Although the amino acid sequence proximal to palmitoylated cysteines may play a critical role (e.g., [23] ), other domains and amino acids, distant from palmitoylated cysteines, likely also contribute to DHHC3 substrate specificity [42] . In this regard, the seven membrane proximal cysteines in b4 (of which at least five may be palmitoylated [19] ) show no discernible similarity to amino acid sequences in other reported DHHC3 substrates, such as G protein alpha subunits, or integrin a6 subunit. Furthermore, knockdown of DHHC3 diminished palmitoylation of the integrin a6 subunit, but not the a3 subunit, even though in both cases the target cysteine is flanked by the same amino acids (-LWKCGFFKR-) at the transmembrane-cytoplasmic interface.
In the case of a6b4, the b4 protein might participate in recruitment of DHHC3 into proximity with both b4 and a6 in the Golgi. This would explain why a3b1 was unaffected by DHHC3. Consistent with a role for b4 in DHHC3 recruitment to a6, preliminary experiments indicate that DHHC3 knockdown did not affect palmitoylation of a6b1 in cells that lacked a6b4 (not shown).
Functional consequences of DHHC3-mediated a6b4 palmitoylation
Functional studies were chosen that specifically involve contributions from a6 and/or b4. Upon ablation of DHHC3, we observed a marked decrease in a6b4 palmitoylation, accompanied by impaired a6 integrin-dependent cell cable formation on 3D Matrigel. Matrigel cable formation results from tensional forces, acting through a6 integrin, which enables cell migration along ''matrix guidance pathways'' leading to formation of a network of cellular cables [43, 44] . DHHC3 ablation also diminished a6 and b4-dependent signaling, as evidenced by decreased antibody-triggered Src phosphorylation. Integrin a6b4 signaling through Src helps to regulate cancer cell motility and invasion [45] . We also noted that loss of b4 palmitoylation was accompanied by decreased phosphorylation of b4 at key sites (S1356 and 1424), which have been linked to hemidesmosome disassembly [36, 37, 40] , a key step in EMT [46] .
However, further studies showed that DHHC3 ablation caused a loss of endogenous a6b4 integrin expression on the cell surface, which likely explains reduced integrin-dependent functions. This result is in sharp contrast to results from b4 mutagenesis experiments [18, 19] . In those studies, b4 lacking palmitoylation was readily expressed on the surface of multiple cell types [18, 19] . With mutant b4 being expressed on cells, it was possible to show that b4 palmitoylation contributes to integrin-dependent cell signaling, spreading and proliferation [18, 19] , as well as association with tetraspanin proteins such as CD9, CD81, and CD63 [18] .
One major reason for the discrepancy between b4 mutagenesis results and DHHC3 ablation results may be that b4 mutants were analyzed when overexpressed [18, 19] , whereas DHHC3 ablation was analyzed for effects on endogenous b4. Indeed in our own experiments, DHHC3 ablation caused loss of cell-surface expression for endogenous a6b4 (in PC3 and MDA-MB-231 cells), but not for a6b4 overexpressed in HEK293 cells. We suspect that for overexpressed a6b4, the normal cellular machinery for processing unpalmitoylated protein may be unavailable or insufficient. These findings emphasize that results based exclusively on overexpression of DHHC enzyme and/or substrate must be interpreted cautiously. Another reason that mutagenesis results could be erroneous is that replacement of cysteines by other amino acids may do more than simply prevent palmitoylation. Conceivably, removal of cysteines could additionally affect secondary structure, protein-protein interactions, protein stability, and/or sensitivity to proteolytic degradation. Further emphasizing the difficulty in interpreting cysteine-palmitoylation site mutagenesis results, replacement of cysteines can yield strikingly different results, depending on which replacement amino acids are used [47] .
Loss of a6b4 stability and surface expression In HEK293 cells, knockdown of DHHC3 did not decrease expression of a6b4. Consequently, a decrease in the amount of palmitoylation/protein could be readily observed. However, for endogenously expressed a6b4, DHHC3 ablation led to decreased a6b4 expression, as seen by immunoblotting, immunofluorescence microscopy, and cell-surface staining. Consequently, a decrease in palmitoylation/protein was not seen unless proteolytic degradation of b4 was blocked. This was best achieved using Pepstatin A, commonly used to inhibit cathepsin D, a lysosomal/endosomal aspartyl protease [48, 49] . Degradation of b4 was not appreciably rescued by bafilomycin-A1, a vacuolar-type H ? -ATPase inhibitor that blocks lysosome acidification and protein degradation [50] . Integrin b4 was also not rescued by other inhibitors of lysosomes (chloroquine, NH 4 Cl; not shown) or inhibitors of lysosomal enzymes (leupeptin, E64). These results suggest that unpalmitoylated b4 is not degraded in lysosomes, but rather by cathepsin D in endosomes. By contrast, unpalmitoylated tetraspanin proteins resulting from DHHC2 ablation were degraded in lysosomes [24] .
Upon addition of Pepstatin A, intracellular b4 was rescued from proteolysis to a markedly greater extent than cell DHHC3 palmitoylates a6b4 integrin 2241 surface b4. These results indicate that unpalmitoylated b4, despite rescue from proteolysis, is still unable to reach the cell surface. We speculate that inability to associate with tetraspanin proteins such as CD9, CD81, CD63 (as seen previously for palmitoylation-deficient mutant b4 [18] ) may play a role in preventing cell-surface expression. In this regard, loss of association with tetraspanins CD9 and CD81 prevented MT1-MMP from reaching the cell surface [51] . DHHC3 ablation did not diminish the cell-surface expression of ten other proteins, consistent with DHHC3 directly and selectively affecting a6b4. Because DHHC3 has an unknown number of other substrates, besides a6b4, indirect effects of DHHC3 ablation on a6b4 plasma membrane targeting are possible. However, indirect effects are unlikely to be a major issue for the several reasons. First, indirect effects, caused by DHHC3 ablation, would be expected to affect plasma membrane targeting of both palmitoylated and unpalmitoylated a6b4 to a similar extent. However, that is not the case. In the presence of Pepstatin A, DHHC3 ablation caused only a 12.9% decrease in palmitoylation/protein for cell surface b4, but a 41.4% loss for intracellular b4 (Supplemental Table 1 ). Hence, the subset of b4, which remains palmitoylated, is preferentially getting to the cell surface, whereas the unpalmitoylated population is more enriched intracellularly. Second, if there were indirect effects, they would need to be very specific. Whereas cellsurface expression of a6 and b4 decreased, there was no decrease in molecules related to a6b4 (other integrins a3b1 and a2b1), molecules associated with a6b4 (tetraspanins CD81, CD9, and CD82), and assorted other molecules (EWI-F, CD98, MHC1, CD147) in response to DHHC3 ablation (Supplemental Fig. S3 ). Third, there is ample precedent for DHHC-type enzymes directly affecting membrane targeting of proteins [52] [53] [54] . However, we could not find any published examples of DHHC-type enzymes having indirect effects on membrane targeting events.
Summary and implications
Despite the functional importance of a6b4 palmitoylation [18, 19] , the responsible PAT had not been identified. Now we show that DHHC3 is largely responsible for a6b4 palmitoylation in 3 different cell lines. Given the wide expression of DHHC3 (see Gene Expression Atlas), it should be available to palmitoylate widely expressed a6b4 in many, if not all cell types. Here we have uncovered a new approach, through DHHC3, by which to modulate the expression and function of a6b4. Because a6b4 plays key roles on nearly all epithelial cells and on many other normal and cancer cell types, we predict that DHHC3 may also be needed to support a6b4 expression and function in those same cells. On cancer cells a6 integrins contribute to tumor initiation, growth, invasion, metastasis, EMT, and drug resistance [9] [10] [11] [12] [13] [14] . Consequently, these integrins have emerged as potential cancer drug targets. Gene expression for ZDHHC3 is elevated in several malignant cell lines from prostate, breast and colorectal cancers, and also from patient prostate and breast carcinoma samples [55] . Hence, it may be reasonable to affect a6 integrin expression and function in cancer cells by targeting DHHC3.
